title: [Influence of immunocorrection on the inflammatory process in the urogenital tract in men with infertility].
abstract: We studied the concentration of metalloproteinases, pro-and anti-inflammatory cytokines, lymphocyte activation markers in seminal plasma of men with oligosymptomatic forms of chronic inflammation of the urogenital tract complicated with infertility. It was shown that chronic inflammation of the urogenital tract shifts the levels of cytokine profile, reduces the concentration of metalloproteinase-2 (576.4 +/- 89.3 ng/ml, P < 0.001), chemokines - fractalkine (16.3 +/- 1.3 pg/ml, P < 0.001) and chemmmokine regulated by activation, expression and secretion of normal T-cells (RANTES (12.7 +/- 1.0 pg/ ml, P < 0.001). Additionally, we observed a sharp increase in IL-8 (215.5 +/- 7.8 pg/ml, P < 0.01), MCP-1 (926.4 +/- 30.2 pg/ml, P < 0.001) and elevation of the CD25 + / CD95 + ratio. These observations point for alterations in apoptotic mechanisms in pathological forms of the generative cells and their accumulation in the sperm. Prolonged inflammation of the genital area is accompanied by depletion of the local immune system resulting in the development of infertility. The multidirectional shifts in IL-10/IL-12 index have been established: an increase in the group of patients with elevated level of hypercapitated spermatozoa and its reduction in microsomatic morphotype of spermatozoa. These data emphasize the importance of the microenvironment in maturation of gametes. It was shown that an inclusion of alfagin and gepatomax in immunorehabilitation of men with oligosymptomatic forms of urogenital infections improves leukocyte subpopulation content of sperm and concentrations of pro-and anti-inflammatory cytokines, and therefore, results in an increase in fertilizing potential.
authors.forename: S Iu
authors.initials: SIu
authors.lastname: Tsiporenko
mesh_terms: D000276:Adjuvants, Immunologic / Q000008:administration & dosage / Q000627:therapeutic use*; D000328:Adult; D017209:Apoptosis / Q000187:drug effects; D016207:Cytokines / Q000276:immunology*; D004359:Drug Therapy, Combination; D006801:Humans; D007248:Infertility, Male / Q000150:complications / Q000188:drug therapy* / Q000201:enzymology / Q000276:immunology; D008297:Male; D052801:Male Urogenital Diseases / Q000150:complications / Q000188:drug therapy* / Q000201:enzymology / Q000276:immunology; D020778:Matrix Metalloproteinase 2 / Q000378:metabolism; D028321:Plant Preparations / Q000008:administration & dosage / Q000627:therapeutic use*; D012661:Semen / Q000187:drug effects* / Q000276:immunology; D013094:Spermatozoa / Q000187:drug effects / Q000276:immunology / Q000473:pathology; D055815:Young Adult
chemical_list: D000276:Adjuvants, Immunologic; D016207:Cytokines; D028321:Plant Preparations; D020778:Matrix Metalloproteinase 2